A Randomized, Open-Label Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Pharmacodynamics ofGSK1362885 in Subjects With Type 2 Diabetes Mellitus
Latest Information Update: 08 Oct 2023
At a glance
- Drugs GSK 1362885 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors GSK
- 19 Jun 2010 Results presented at the 92nd Annual Meeting of the Endocrine Society.
- 11 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Nov 2009 New trial record